SCHEMBL5542552

SCHEMBL5542552

COc1ccc(OC)c(CNC=O)c1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
APLNR P35414 1/20 0.53
HSD17B10 Q99714 1/20 0.53
IDO1 P14902 2/20 0.51
ADRA1A P35348 1/20 0.51
TAAR1 Q96RJ0 1/20 0.51
HTR2A P28223 2/20 0.51
HTR2C P28335 1/20 0.51
HDAC3 O15379 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC2 Q92769 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
AOC3 Q16853 1/20 0.50
HIF1A Q16665 1/20 0.49
HTT P42858 1/20 0.49
POLB P06746 1/20 0.48
MEN1 O00255 1/20 0.48
MAPT P10636 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL712690 0.87 APLNR (0.72) APLNRHTR2AHTR2CHDAC3HDAC1
SCHEMBL6506680 0.84 ADRA1A (0.57) HSD17B10IDO1ADRA1ATAAR1HTR2A
SCHEMBL13577792 0.80 APLNR (0.49) APLNRHTTMEN1KMT2A
SCHEMBL14299916 0.79 APLNR (0.61) APLNRHSD17B10IDO1ADRA1ATAAR1
SCHEMBL1254174 0.79 HTR2A (0.65) APLNRHSD17B10IDO1ADRA1ATAAR1
SCHEMBL5540592 0.78 MEN1 (0.53) HSD17B10IDO1ADRA1ATAAR1HTR2A
SCHEMBL7332987 0.78 ADRA1A (0.62) HSD17B10IDO1ADRA1ATAAR1HTR2A
SCHEMBL27163106 0.78 APLNR (0.86) APLNRIDO1ADRA1ATAAR1HTR2A
SCHEMBL885029 0.77 HSD17B10 (0.57) APLNRHSD17B10IDO1ADRA1ATAAR1
SCHEMBL30229484 0.77 HSD17B10 (0.57) APLNRHSD17B10IDO1ADRA1ATAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 APLNR 2778/4885HSD17B10 467/4885IDO1 3181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.